Tissue Expression of Carbonic Anhydrase IX Correlates to More Aggressive Phenotype of Basal Cell Carcinoma.
IHC
basal cell carcinoma
carbonic anhydrase IX
prognosis
risk stratification
skin cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
01
2021
accepted:
05
03
2021
entrez:
12
4
2021
pubmed:
13
4
2021
medline:
13
4
2021
Statut:
epublish
Résumé
Basal cell carcinoma (BCC) is the most common cancer in the white-skinned population accounting for about 15% of all neoplasms. Its incidence is increasing worldwide, at a rate of about 10% per year. BCC, although infrequently metastasizing, very often causes extensive tissue losses, due to the high propensity toward stromal infiltration, particularly in its dedifferentiated forms, with disfiguring and debilitating results. To date, there still is limited availability of therapeutic treatments alternative to surgery. We evaluated the immunohistochemical expression of the carbonic anhydrase IX (CAIX), one of the main markers of tissue hypoxia, in a set of 85 archived FFPE BCC tissues, including the main subtypes, with different clinical outcomes, to demonstrate a possible relationship between hypoxic phenotype and biological aggressiveness of these neoplasms. Our results showed that the expression level of the CAIX protein contributes to the stratification of BCC in the different risk classes for recurrence. We hypothesize for CAIX a potential therapeutic role as a target therapy in the treatment of more aggressive BCCs, thus providing an alternative to surgical and pharmacological therapy with Hedgehog inhibitors, a promising example of target therapy in BCCs.
Identifiants
pubmed: 33842375
doi: 10.3389/fonc.2021.659332
pmc: PMC8027352
doi:
Types de publication
Journal Article
Langues
eng
Pagination
659332Informations de copyright
Copyright © 2021 Russo, Varricchio, Ilardi, Martino, Di Crescenzo, Pignatiello, Scalvenzi, Costa, Mascolo, Merolla and Staibano.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JOP. 2001 Jul;2(4 Suppl):159-64
pubmed: 11875253
J Clin Oncol. 2003 Feb 1;21(3):473-82
pubmed: 12560438
Curr Med Chem. 2014;21(14):1569-82
pubmed: 23992304
Br J Cancer. 2007 Jan 15;96(1):104-9
pubmed: 17213826
Eur J Pharm Sci. 2019 Oct 1;138:105012
pubmed: 31330259
Histopathology. 2020 Oct;77(4):659-666
pubmed: 32639054
JAMA. 2005 Aug 10;294(6):681-90
pubmed: 16091570
Metabolites. 2017 Sep 16;7(3):
pubmed: 28926956
Br J Dermatol. 2012 May;166(5):1069-80
pubmed: 22251204
Bioorg Med Chem. 2020 May 1;28(9):115424
pubmed: 32209296
Oncotarget. 2017 Apr 25;8(17):28650-28659
pubmed: 28404916
Cancer Metastasis Rev. 2007 Jun;26(2):225-39
pubmed: 17440684
Int J Mol Sci. 2020 Apr 23;21(8):
pubmed: 32340282
J Oral Pathol Med. 2013 Jan;42(1):1-8
pubmed: 22417164
Cancer Immunol Res. 2019 Jul;7(7):1064-1078
pubmed: 31088846
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1258-1266
pubmed: 32466707
Sci Rep. 2020 Nov 6;10(1):19274
pubmed: 33159147
Adv Exp Med Biol. 2020;1268:123-139
pubmed: 32918216
Cancers (Basel). 2020 May 25;12(5):
pubmed: 32466184
Cancer Metastasis Rev. 2019 Jun;38(1-2):65-77
pubmed: 31076951
Curr Med Chem. 2008;15(4):322-38
pubmed: 18288988
Biochim Biophys Acta. 2010 Feb;1804(2):404-9
pubmed: 19679200
Int J Mol Sci. 2012;13(9):11044-62
pubmed: 23109837
Epidemiol Prev. 2011 Sep-Dec;35(5-6 Suppl 3):1-200
pubmed: 22166893
Br J Dermatol. 2017 Aug;177(2):359-372
pubmed: 28220485
An Bras Dermatol. 2011 Mar-Apr;86(2):292-305
pubmed: 21603813
Theranostics. 2017 Sep 26;7(17):4322-4339
pubmed: 29158829
Cancers (Basel). 2020 Oct 17;12(10):
pubmed: 33080820
Virchows Arch. 2016 Aug;469(2):183-90
pubmed: 27184798
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1185-1193
pubmed: 32396749
N Engl J Med. 2006 Nov 9;355(19):1967-77
pubmed: 17093248